• ALK-Abelló expanded its long-running contract manufacturing partnership with Catalent for Zydis fast-dissolving tablet technology.
• Deal secures prioritized manufacturing capacity, lifting annual output about 40% to 1.1 billion tablets from the early 2030s.
• ALK will commit about DKK 500 million over three years to fund capacity expansion at Catalent.
• Payments will be capitalized as prepayments, then amortized over the contract; manufacturing cost savings are expected to offset the upfront spend.
• Agreement leaves 2026 guidance, long-term financial targets unchanged.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ALK-Abelló A/S published the original content used to generate this news brief on September 30, 2026, and is solely responsible for the information contained therein.